Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How INO compares with its peers on the latest reported figures

  • INO's FY2025 gross margin of 100.0% is the highest of the 8 companies compared; the peer median is 48.3%.
  • Its year-over-year change of +0.0 pp is the 6th highest of 7, against a peer median of +52.5 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +0.0 pp.
INO Competitors Peer median
Gross Margin for INO and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
SPROSpero Therapeutics, Inc.LTM Mar 2026100.0% +296.0 pp+0.0 pp
AGENAgenus Inc.LTM Mar 202652.1% +86.4 pp+130.9 pp
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
SEERSeer, Inc.LTM Mar 202648.3% +18.6 pp+9.2 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding INO) 48.3%+52.5 pp+0.0 pp

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77M10.26M832.01K217.76K65.34K
Cost of Revenue00000
Gross Profit1.77M10.26M832.01K217.76K65.34K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development249.24M187.65M86.68M75.62M54.21M
Selling, General & Admin53.75M90.19M47.58M37M32.68M
Operating Expenses302.99M277.84M144.77M112.62M86.89M
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
EBITDA(296.56M)(270.9M)(130.39M)(103.95M)(81.96M)
EBITDA Margin-16709.7%-2639.8%-15671.8%-47735.2%-125425.9%
Operating Income(301.22M)(267.57M)(143.94M)(112.4M)(86.82M)
Operating Margin-16972.3%-2607.4%-17300.3%-51616.9%-132871.3%
Interest Income3.36M4.78M8.13M4.77M2.42M
Interest Expense1.94M1.25M1.22M177.83K0
Other Income / Expenses(2.44M)(12.24M)8.82M5.14M1.88M
Income Before Tax(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Pre-Tax Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
Income Tax Expense00000
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Net Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
EPS (Basic)(1.42)(14.07)(6.09)(3.95)(1.81)
EPS (Diluted)(1.42)(14.07)(6.09)(3.95)(1.81)
Weighted Avg Shares214.62M19.89M22.17M27.16M468.86M
Weighted Avg Shares (Diluted)214.62M19.89M22.17M27.16M468.86M

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.